>

Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

April 13-14, 2018

New York, New York

Continuing Education

ACCMEPhysicians
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex designates this conference for a maximum of 12.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing
This activity has been planned and implemented in accordance with the Essential Areas and policies of the American Nurses Credentialing Center (ANCC) through the joint providership of North American Center for Continuing Medical Education, LLC (NACCME), and Imedex. The North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. This continuing nursing education activity awards 12.5 contact hours

Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.5 contact hours.

Pharmacy
Imedex, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge activity (0408-0000-18-004-L01-P) has been approved for a maximum of 12.25 contact hours (1.225 CEUs). To receive credit, participants must complete an activity evaluation survey. In order to claim credit in a timely matter, you must submit your evaluation and credit request within 60 days (deadline is 6/12/2018).

Pharmacists must be able to provide their correct NABP number and DOB (MM/DD). Imedex is responsible for submitting data through CPE Monitor.


MAINTENANCE OF CERTIFICATION – ABIM

Successful completion of this CME activity enables a participant to earn up to 12.5 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points. Participants will have only 60 days following the activity to claim MOC points.

Who Should Attend

These live educational activities are designed to meet the educational needs of U.S. hematologists, medical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.

Objectives

Upon successful completion of these educational activities, participants should be able to:

    • Interpret pertinent clinical trial data for standard of care and novel management strategies for hematologic malignancies and benign hematologic disorders
    • Assess how integration relevant clinical trial data into clinical practice has the potential to enhance outcomes in patients with hematologic malignancies and benign hematologic disorders
    • Assess how molecular and genetic abnormalities can be utilized in diagnosis, prognosis, risk stratification and therapy selection for patients with hematologic malignancies and benign hematologic disorders
    • Evaluate the sequencing strategies in the era of novel immunotherapies, targeted therapies, and stem cell transplants
    • Evaluate the mechanism of action of standard of care and novel therapeutic agents
    • Define patient populations who would gain the most clinical benefit from the utilization of standard of care and novel therapeutic agents
    • Formulate evidence-based strategies for the management of hematologic malignancies and benign hematologic disorders that take into consideration patient risk factors, cost, disease stage, and prior therapeutic regimens